Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research found that combining a 308-nm excimer laser with oral compound glycyrrhizin and topical 0.03% tacrolimus was more effective for treating pediatric facial and cervical vitiligo, resulting in faster and higher rates of repigmentation with minimal adverse effects compared to glycyrrhizin and tacrolimus alone.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.

Triamcinolone acetonide injections help regrow hair in alopecia areata patients.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this study, intralesional triamcinolone acetonide combined with 5-fluorouracil was more effective for treating keloids, showing a good to excellent response in 95% of cases and fewer side effects, compared to triamcinolone acetonide alone, which achieved a 70% response rate.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

This integrative review found that triamcinolone hexacetonide remains the primary treatment for mild to moderate alopecia areata but noted its significant side effects with prolonged use, while emerging therapies like PRP and minoxidil offer promising alternative benefits with fewer risks.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study showed that intralesional injections of pentoxifylline may be an effective and safe alternative to triamcinolone acetonide for treating localized alopecia areata.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.

In this case report, a combination treatment of intralesional triamcinolone acetonide, oral acitretin, and topical clobetasol propionate showed effectiveness in reducing symptoms of Graham-Little-Piccardi-Lasseur syndrome in one patient over two months, with no new areas of hair loss observed.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This review provides guidelines for physicians on using hormonal therapies, such as androgen receptor blockers and oral contraceptives, to treat hormonally related acne, but reports no new clinical findings.

This report describes two renal transplant patients whose hair loss improved after switching from tacrolimus to cyclosporine, suggesting that cyclosporine might counteract steroid-induced alopecia.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

In this study on patchy alopecia areata treatment involving 20 patients, TCA (triamcinolone acetonide) injections showed a significantly better response and minimal side effects compared to superficial cryotherapy.

Tofacitinib may effectively treat folliculitis decalvans.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.